NLRP3 and Alzheimer disease: This pilot study aimed to evaluate, in ex vivo, the effectiveness of glibenclamide-loaded nanovectors (GNV) in suppressing NLRP3 inflammasome activation in monocytes from AD patients and healthy controls.